| CAS NO: | 2474876-09-8 |
| 包装 | 价格(元) |
| 1mg | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
| Cas No. | 2474876-09-8 |
| 别名 | iBET-BD2 |
| Canonical SMILES | O[C@H]1CC[C@H](NC(C2=CC(F)=C(NC(C)=O)C(O[C@@H](C)C3=CC=CC=C3)=C2)=O)CC1 |
| 分子式 | C23H27FN2O4 |
| 分子量 | 414.5 |
| 溶解度 | DMSO: soluble |
| 储存条件 | -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | iBET-BD2 is an inhibitor of the bromodomain and extra-terminal domain (BET) family protein bromodomain 2 (BD2).1It inhibits BD2 in bromodomain-containing protein 2 (BRD2), BRD3, BRD4, and BRDT (IC50s = 264, 98, 49, and 214 nM, respectively) and is selective for BD2 over BD1 (IC50s = 10.96, 36.31, 70.55, and >50.11 µM for BRD2, BRD3, BRD4, and BDT, respectively) in a time-resolved FRET (TR-FRET) assay. iBET-BD2 (1 µM) inhibits IFN-γ-induced protein expression of MHC class I in K562 cells. It reduces the production of anti-KLH IgM antibodies in mice immunized with keyhole limpet hemocyanin (KLH) when administered at a dose of 40 mg/kg. 1.Gilan, O., Rioja, I., Knezevic, K., et al.Selective targeting of BD1 and BD2 of the BET proteins in cancer and immuno-inflammationScience368(6489)387-394(2020) |
m.cnreagent.com